Natural Product (NP) Details

General Information of the NP (ID: NP2691)
Name
Spectinomycin
Synonyms
Spectinomycin; actinospectacin; Trobicin; Espectinomicina; Togamycin; 1695-77-8; Antibiotic 2233wp; Spectam; Spectinomycine; Spectinomycinum; Spectinomicina [Italian]; Actinospectacina [Italian]; Spectinomycine [INN-French]; Spectinomycinum [INN-Latin]; Espectinomicina [INN-Spanish]; Spectinomycin hydrochloride; UNII-93AKI1U6QF; M-141; 93AKI1U6QF; CHEBI:9215; SCM; 4H-Pyrano[2,3-b][1,4]benzodioxin-4-one, decahydro-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)-, (2R,4aR,5aR,6S,7S,8R,9S,9aR,10aS)-; Actinospectacina; (2R,4aR,5aR,6S,7S,8R,9S,9aR,10aS)-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)decahydro-4H-pyrano[2,3-b][1,4]benzodioxin-4-one; M 141; U 18409; 22189-32-8; Spectinomycin [INN:BAN]; (1R,3S,5R,8R,10R,11S,12S,13R,14S)-8,12,14-trihydroxy-5-methyl-11,13-bis(methylamino)-2,4,9-trioxatricyclo[8.4.0.03,8]tetradecan-7-one; U 18409 E; XK 43-1; C14H24N2O7; 21736-83-4; U-18409E; EINECS 216-911-3; Spectinomycin HCl/ Sulphate; BRN 2171701; Specitinomycin; SR-05000001868; (2R,4aR,5aR,6S,7S,8R,9S,9aR,10aS)-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)-3,5a,6,7,8,9,9a,10a-octahydro-2H-benzo[[?]]pyrano[[?]][1,4]dioxin-4-one; 4H-Pyrano(2,3-b)(1,4)benzodioxin-4-one, decahydro-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)-; 4H-Pyrano(2,3-b)(1,4)benzodioxin-4-one, decahydro-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)-, (2R,4aR,5aR,6S,7S,8R,9S,9aR,10aS)-; Prospec (TN); Adspec (TN); SPCM; Spectinomycin (INN); NSC132679; Spectrum_000954; Prestwick0_000804; Prestwick1_000804; Prestwick2_000804; Prestwick3_000804; Spectrum2_001315; Spectrum3_000898; Spectrum4_000993; Spectrum5_001407; SCHEMBL3533; CHEMBL1167; BSPBio_000667; KBioGR_001425; KBioSS_001434; DivK1c_000137; SPBio_001409; SPBio_002588; BPBio1_000735; DTXSID9023592; GTPL11127; KBio1_000137; KBio2_001434; KBio2_004002; KBio2_006570; KBio3_001816; NINDS_000137; HMS2089C03; CHX-3101; ZINC53006806; AKOS015961272; CCG-208273; DB00919; IDI1_000137; SMP1_000276; NCGC00017354-02; NCGC00017354-03; NCGC00017354-04; NCGC00142531-01; NCGC00142531-02; AC-13570; NCI60_000023; O212; ST066911; SBI-0051514.P003; C02078; D08526; U18409; AB00642548-10; AB00642548-11; AB00642548_12; AB00642548_13; Q416154; U-18409; ACTINOSPECTACIN; ESPECTINOMICINA; CHX-3101; SR-05000001868-4; ETHYL2-ANILINO-4-CHLORO-5-FORMYL-3-THIOPHENECARBOXYLATE; (1R,3S,5R,8R,10R,11S,12S,13R,14S)-8,12,14-trihydroxy-5-methyl-11,13-bis(methylamino)-2,4,9-trioxatricyclo[8.4.0.0^{3,8}]tetradecan-7-one; (8S,11S,13S,14S,3R,6R,10R,12R)-12,14-bis(methylamino)-3,11,13-trihydroxy-6-met hyl-2,7,9-trioxatricyclo[8.4.0.0<3,8>]tetradecan-4-one
    Click to Show/Hide
Species Origin Legionella pneumophila ...     Click to Show/Hide
Legionella pneumophila
SuperKingdom: Bacteria
Phylum: Proteobacteria
Class: Gammaproteobacteria
Order: Legionellales
Family: Legionellaceae
Genus: Legionella
Species: Legionella pneumophila
Disease Bacterial infection [ICD-11: 1A00-1C4Z] Approved [1]
Structure
Click to Download Mol
2D MOL

3D MOL

ADMET Property
Absporption
Caco-2 Permeability
 -5.597
 
MDCK Permeability
 -5.073
 
PAMPA
 +++
 
HIA
 -
 
Distribution
VDss
 -0.843
 
PPB
 9.3%
 
BBB
 - - -
 
Metabolism
CYP1A2 inhibitor
 - - -
CYP1A2 substrate
 - - -
CYP2C19 inhibitor
 - - -
CYP2C19 substrate
 - - -
CYP2C9 inhibitor
 - - -
CYP2C9 substrate
 - - -
CYP2D6 inhibitor
 - - -
CYP2D6 substrate
 - - -
CYP3A4 inhibitor
 - - -
CYP3A4 substrate
 - - -
CYP2B6 inhibitor
 - - -
CYP2B6 substrate
 - - -
CYP2C8 inhibitor
 - - -
HLM Stability
 - -
 
Excretion
CLplasma
 0.562
 
T1/2
 3.124
Toxicity
DILI
 +
 
Rat Oral Acute Toxicity
 - - -
 
FDAMDD
 - - -
 
Respiratory
 - - -
 
Human Hepatotoxicity
 ++
 
Ototoxicity
 ++
 
Drug-induced Nephrotoxicity
 +++
 
Drug-induced Neurotoxicity
 - - -
 
Hematotoxicity
 -
 
Genotoxicity
 +++
 
Tips: 1. For the classification endpoints, the prediction probability values are transformed into six symbols: 0-0.1 (- - -), 0.1-0.3 (- -), 0.3-0.5 (-), 0.5-0.7 (+), 0.7-0.9 (++), and 0.9-1.0 (+++). 2. Additionally, the corresponding relationships of the three labels are as follows: excellent; medium; poor.
    Click to Show/Hide
    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C14H24N2O7
PubChem CID
15541
Canonical SMILES
CC1CC(=O)C2(C(O1)OC3C(C(C(C(C3O2)NC)O)NC)O)O
InChI
1S/C14H24N2O7/c1-5-4-6(17)14(20)13(21-5)22-12-10(19)7(15-2)9(18)8(16-3)11(12)23-14/h5,7-13,15-16,18-20H,4H2,1-3H3/t5-,7-,8+,9+,10+,11-,12-,13+,14+/m1/s1
InChIKey
UNFWWIHTNXNPBV-WXKVUWSESA-N
CAS Number
CAS 1695-77-8
ChEBI ID
CHEBI:9215
TTD Drug ID
D02PCR
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP
          Erythromycin      Bacterial infection     Click to Show/Hide the Molecular Data of This Drug
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vitro Model Chlamydia trachomatis strains Microorganism model Chlamydia trachomatis
                    Experimental
                    Result(s)		 A combination of spectinomycin with erythromycin was found to be more effective against Chlamydia trachomatis.
          Doxycycline      Periodontal disease     Click to Show/Hide the Molecular Data of This Drug
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vitro Model Chlamydia trachomatis strains Microorganism model Chlamydia trachomatis
                    Experimental
                    Result(s)		 A combination of spectinomycin with doxycycline was found to be more effective against Chlamydia trachomatis.
Target and Pathway
Target(s) Staphylococcus 30S ribosomal subunit (Stap-coc pbp2)  Molecule Info  [3]
References
Reference 1 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 050347.
Reference 2 In vitro effects of spectinomycin and ceftriaxone alone or in combination with other antibiotics against Chlamydia trachomatis. Antimicrob Agents Chemother. 2005 Apr;49(4):1584-6.
Reference 3 Functional insights from the structure of the 30S ribosomal subunit and its interactions with antibiotics. Nature. 2000 Sep 21;407(6802):340-8.
 Download Picture         KEGG Link